Abstract
Plasma butyrylcholinesterase (BChE) is important in the metabolism of cocaine, but natural human BChE has limited therapeutic potential for detoxication because of low catalytic efficiency with cocaine. Here we report pharmacokinetics of cocaine in rats treated with A328W/Y332A BChE, an excellent cocaine hydrolase designed with the aid of molecular modeling. Compared with wild-type BChE, this enzyme hydrolyzes cocaine with 40-fold improvedkcat (154 min−1 versus 4.1 min−1) and only slightly increasedKM (18 μM versus 4.5 μM). In rats given this hydrolase (3 mg/kg i.v.) 10 min before cocaine challenge (6.8 mg/kg i.v.), cocaine half-life was reduced from 52 min to 18 min. Mirroring the reductions of plasma cocaine were large increases in benzoic acid, a product of BChE-mediated cocaine hydrolysis. All other pharmacokinetic parameters confirmed a large, dose-dependent acceleration of cocaine removal by the injected cocaine hydrolase. These results show that A328W/Y332A, an efficient cocaine hydrolase in vivo as well as in vitro, might promote cocaine detoxication in a clinical setting.
Footnotes
- Abbreviations:
- BChE
- butyrylcholinesterase
- iso-OMPA
- tetraisopropyl pyrophosphoramide
- LC-MS
- liquid chromatography-mass spectrometry
- BE
- benzoylecgonine
- EME
- ecgonine methyl ester
- CL
- clearance
- Vss
- volume of distribution at steady state
- AUC0→∞
- area under the curve from time 0 to final sample
- AUMC0→∞
- area under the first moment curve from time 0 to final sample
- CLtotal
- total clearance from plasma
- Received February 5, 2002.
- Accepted April 5, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|